MarketScreener Homepage > Equities > Hong Kong Stock Exchange > Sinopharm Group Co., Ltd. 1099 CNE100000FN7

Report

End-of-day quote Hong Kong Stock Exchange - 10/23
17.82	HKD		+5.07%

10/22

SINOPHARM : Nine-Month Net Profit Rose 7.9%

10/20

China's Sinovac vaccine to be included in Brazil's immunization program, governors say

10/20

China's Sinovac vaccine to be included in Brazil's immunization program, governors say

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Hong Kong Stock Exchange

10/19/2020	10/20/2020	10/21/2020	10/22/2020	10/23/2020	Date
15.9	16.2	16.9	16.96	17.82	Last
10261340	10019010	23811050	12526200	22156840	Volume
-1.12%	+1.89%	+4.32%	+0.36%	+5.07%	Change

Financials

Sales 2020	462 B 68 773 M 68 773 M
Net income 2020	6 704 M 999 M 999 M
Net Debt 2020	15 485 M 2 307 M 2 307 M
P/E ratio 2020	7,05x
Yield 2020	4,21%

Sales 2021	524 B 78 036 M 78 036 M
Net income 2021	7 551 M 1 125 M 1 125 M
Net Debt 2021	21 271 M 3 169 M 3 169 M
P/E ratio 2021	6,27x
Yield 2021	4,63%

Capitalization	47 901 M 7 166 M 7 137 M
EV / Sales 2020	0,14x
EV / Sales 2021	0,13x
Nbr of Employees	93 764
Free-Float	43,0%

More Financials

Company

Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments. The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics. The Retail Pharmacy segment is engaged in...

Sector

Drug Retailers

Calendar

03/19

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Sinopharm Group Co., Ltd.

Trading Rating :

Investor Rating :

More Ratings

All news about SINOPHARM GROUP CO., LTD.

10/22	SINOPHARM : Nine-Month Net Profit Rose 7.9%	DJ
10/20	China's Sinovac vaccine to be included in Brazil's immunization program, gove..	RE
10/20	China's Sinovac vaccine to be included in Brazil's immunization program, gove..	RE
10/20	SINOPHARM GROUP CO., LTD. : quaterly earnings release
10/19	Brazil's Butantan says tests show vaccine by China's Sinovac is safe	RE
10/15	Coronavirus vaccine candidate from China's CNBG shows promise in human test, ..	RE
10/15	China's Sinopharm offers experimental COVID-19 vaccines to students - WSJ	RE
09/27	SINOPHARM : Announcements and Notices - ANNOUNCEMENT POLL RESULTS OF THE EXTRAOR..	PU
09/27	SINOPHARM : Announcements and Notices - NOTICE OF EXTRAORDINARY GENERAL MEETING	PU
09/27	SINOPHARM : Announcements and Notices - ANNOUNCEMENT ELECTION OF CHAIRMAN AND VI..	PU
09/27	SINOPHARM : Announcements and Notices - List of Directors and Their Role and Fun..	PU
09/24	China's Sinovac expects interim final-stage trial data on coronavirus vaccine..	RE
09/24	China's CNBG to donate 200,000 coronavirus vaccine doses to medics in Wuhan	RE
09/24	China's CNBG to donate 200,000 coronavirus vaccine doses to medics in Wuhan	RE
09/22	Chinese state-backed firm expects coronavirus vaccine approval for public use..	RE

More news

News in other languages on SINOPHARM GROUP CO., LTD.

10/20	SINOPHARM GROUP CO., LTD. : Veröffentlichung des Quartalsergebnisses
10/20	SINOPHARM GROUP CO., LTD. : publication des résultats trimestriels
10/15	VACCIN CONTRE LE COVID-19 : trop vite, trop haut, trop fort?
09/25	CORONAVIRUS : la Chine espère produire 610 millions de doses/an de vaccins
09/15	CORONAVIRUS : la Chine évoque un potentiel vaccin pour novembre

More news

Provided by Scoopnest.com

Analysis

Alibaba, Xiaomi to join Hong Kong's Hang Seng Index

More Must read

Chart SINOPHARM GROUP CO., LTD.

Duration : Period :

Sinopharm Group Co., Ltd. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends SINOPHARM GROUP CO., LTD.

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bearish	Bearish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	21
Average target price	23,07 CNY
Last Close Price	15,37 CNY
Spread / Highest target	136%
Spread / Average Target	50,1%
Spread / Lowest Target	-6,24%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Yong Liu	President & Executive Director
Fang Yao	Chairman-Supervisory Board
Zhi Ming Li	Chairman
Xiu Chang Jiang	Chief Financial Officer & Vice President
Jin Dong Deng	Non-Executive Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

SINOPHARM GROUP CO., LTD.	-37.36%	7 166



WALGREENS BOOTS ALLIANCE, INC.	-35.48%	32 939
MCKESSON CORPORATION	13.08%	25 368
CARDINAL HEALTH, INC.	-2.45%	14 476
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	92.41%	8 223
WELCIA HOLDINGS CO., LTD.	17.12%	8 117

More Results